{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:27:34Z","timestamp":1648708054101},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T00:00:00Z","timestamp":1439424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s10555-015-9581-1","type":"journal-article","created":{"date-parts":[[2015,8,12]],"date-time":"2015-08-12T05:58:38Z","timestamp":1439359118000},"page":"511-525","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review"],"prefix":"10.1007","volume":"34","author":[{"given":"Fernando","family":"Mendes","sequence":"first","affiliation":[]},{"given":"C\u00e1tia","family":"Domingues","sequence":"additional","affiliation":[]},{"given":"Ricardo","family":"Teixo","sequence":"additional","affiliation":[]},{"given":"Ana Margarida","family":"Abrantes","sequence":"additional","affiliation":[]},{"given":"Ana Cristina","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Nobre-Gois","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Jacobetty","sequence":"additional","affiliation":[]},{"given":"Ana Bela","family":"Sarmento","sequence":"additional","affiliation":[]},{"given":"Maria Filomena","family":"Botelho","sequence":"additional","affiliation":[]},{"given":"Manuel Santos","family":"Rosa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,8,13]]},"reference":[{"issue":"3","key":"9581_CR1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11899-013-0170-5","volume":"8","author":"C Ba","year":"2013","unstructured":"Ba, C. (2013). The role of radiation therapy in the treatment of stage I-II diffuse large B-cell lymphoma. Current Hematologic Malignancy Reports, 8(3), 236\u2013242. doi: 10.1007\/s11899-013-0170-5 .","journal-title":"Current Hematologic Malignancy Reports"},{"issue":"19","key":"9581_CR2","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S., Stein, H., & Jaffe, E. S. (2011). The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 117(19), 5019\u20135032. doi: 10.1182\/blood-2011-01-293050 .","journal-title":"Blood"},{"issue":"5","key":"9581_CR3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/CCO.0b013e32832f3c8b","volume":"21","author":"DO Persky","year":"2009","unstructured":"Persky, D. O., & Miller, T. P. (2009). Localized large cell lymphoma: is there any need for radiation therapy? Current Opinion in Oncology, 21(5), 401\u2013406. doi: 10.1097\/CCO.0b013e32832f3c8b .","journal-title":"Current Opinion in Oncology"},{"issue":"3","key":"9581_CR4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.semradonc.2007.02.002","volume":"17","author":"AK Ng","year":"2007","unstructured":"Ng, A. K. (2007). Diffuse large B-cell lymphoma. Seminars in Radiation Oncology, 17(3), 169\u2013175. doi: 10.1016\/j.semradonc.2007.02.002 .","journal-title":"Seminars in Radiation Oncology"},{"issue":"1","key":"9581_CR5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton, L. M., Wang, S. S., Devesa, S. S., Hartge, P., Weisenburger, D. D., & Linet, M. S. (2006). Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 107(1), 265\u2013276. doi: 10.1182\/blood-2005-06-2508 .","journal-title":"Blood"},{"key":"9581_CR6","doi-asserted-by":"crossref","unstructured":"Tilly, H., Vitolo, U., Walewski, J., da Silva, M. G., Shpilberg, O., Andre, M., \u2026 Dreyling, M. (2012). Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(suppl_7), vii78\u2013vii82. doi: 10.1093\/annonc\/mds273","DOI":"10.1093\/annonc\/mds273"},{"key":"9581_CR7","doi-asserted-by":"crossref","unstructured":"Morgan, G., Vornanen, M., Puitinen, J., Naukkarinen, A, Brincker, H., Olsen, J., \u2026 Cartwright, R. (1997). Changing trends in the incidence of non-Hodgkin\u2019s lymphoma in Europe. Biomed Study Group. Annals of Oncology: Official Journal of the European Society for Medical Oncology \/ ESMO, 8(Suppl 2), 49\u201354.","DOI":"10.1093\/annonc\/8.suppl_2.S49"},{"key":"9581_CR8","unstructured":"Swerdlow SH, Campo E, Harris NL, E. Al. (2008). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. In I. A. for R. on C. Cancer (Ed.), Lyon."},{"key":"9581_CR9","doi-asserted-by":"crossref","unstructured":"Kaminski, M. S., Coleman, C. N., Colby, T. V., Cox, R. S., & Rosenberg, S. A. (1986). Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Annals of Internal Medicine, 104(6), 747\u2013756. Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3518561 .","DOI":"10.7326\/0003-4819-104-6-747"},{"issue":"2","key":"9581_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0360-3016(80)90027-9","volume":"6","author":"S Monfardini","year":"1980","unstructured":"Monfardini, S., Banfi, A., Bonadonna, G., Rilke, F., Milani, F., Valagussa, P., & Lattuada, A. (1980). Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin\u2019s lymphoma. International Journal of Radiation Oncology, Biology, Physics, 6(2), 125\u2013134. doi: 10.1016\/0360-3016(80)90189-3 .","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"9581_CR11","doi-asserted-by":"crossref","unstructured":"Nissen, N. I., Ersb\u00f8ll, J., Hansen, H. S., Walbom-J\u00f8rgensen, S., Pedersen-Bjergaard, J., Hansen, M. M., & Ryg\u00e5rd, J. (1983). A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin\u2019s lymphomas. Cancer, 52(1), 1\u20137. Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6406037 .","DOI":"10.1002\/1097-0142(19830701)52:1<1::AID-CNCR2820520102>3.0.CO;2-M"},{"key":"9581_CR12","doi-asserted-by":"crossref","unstructured":"Hudson, B., Hudson, G., Maclennan, K., Anderson, L., & Linch, D. (1994). Clinical stage-1 Non-Hodgkins-lymphoma\u2014long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Bristish Journal of Cancer, 69, 1088\u20131093. Retrieved from http:\/\/discovery.ucl.ac.uk\/42259\/ .","DOI":"10.1038\/bjc.1994.213"},{"issue":"3","key":"9581_CR13","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini, E., Bacci, F., Sagramoso, C., & Pileri, S. A. (2010). WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica, 102(3), 83\u201387.","journal-title":"Pathologica"},{"issue":"1","key":"9581_CR14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2014","unstructured":"Sehn, L. H., & Gascoyne, R. D. (2014). Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood, 125(1), 22\u201332. doi: 10.1182\/blood-2014-05-577189 .","journal-title":"Blood"},{"key":"9581_CR15","doi-asserted-by":"crossref","unstructured":"Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A, \u2026 Staudt, L.M. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403(February), 503\u2013511. doi: 10.1038\/35000501 .","DOI":"10.1038\/35000501"},{"key":"9581_CR16","doi-asserted-by":"crossref","unstructured":"Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., \u2026 Staudt, L.M. (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346(25), 1937\u20131947. doi: 10.1056\/NEJMoa012914 .","DOI":"10.1056\/NEJMoa012914"},{"key":"9581_CR17","doi-asserted-by":"crossref","unstructured":"Landberg, T.G., H\u00e5kansson, L.G., M\u00f6ller, T.R., Mattsson, W.K., Landys, K.E., Johansson, B. G., \u2026 Dahl, O.G. (1979). CVP-remission-maintenance in stage I or II non-Hodgkin\u2019s lymphomas: preliminary results of a randomized study. Cancer, 44(3), 831\u2013838. Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/383273 .","DOI":"10.1002\/1097-0142(197909)44:3<831::AID-CNCR2820440307>3.0.CO;2-S"},{"key":"9581_CR18","doi-asserted-by":"crossref","unstructured":"Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., \u2026 Staudt, L.M. (2008). Stromal gene signatures in large-B-cell lymphomas. The New England Journal of Medicine, 359(22), 2313\u20132323. doi: 10.1056\/NEJMoa0802885 .","DOI":"10.1056\/NEJMoa0802885"},{"issue":"7277","key":"9581_CR19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"R Davis","year":"2010","unstructured":"Davis, R., Ngo, V., Lenz, G., & Tolar, P. (2010). Chronic Active B cell receptor signaling in diffuse large B cell lymphoma. Nature, 463(7277), 88\u201392. doi: 10.1038\/nature08638.Chronic .","journal-title":"Nature"},{"issue":"15","key":"9581_CR20","first-page":"1648","volume":"43","author":"C Gisselbrecht","year":"1993","unstructured":"Gisselbrecht, C. (1993). Aggressive lymphomas. La Revue du Praticien, 43(15), 1648\u20131653. doi: 10.1056\/NEJMra0807082 .","journal-title":"La Revue du Praticien"},{"issue":"4","key":"9581_CR21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MOH.0b013e3283623d7f","volume":"20","author":"L Pasqualucci","year":"2013","unstructured":"Pasqualucci, L. (2013). The genetic basis of diffuse large B-cell lymphoma. Current Opinion in Hematology, 20(4), 336\u2013344. doi: 10.1097\/MOH.0b013e3283623d7f .","journal-title":"Current Opinion in Hematology"},{"issue":"1","key":"9581_CR22","first-page":"12","volume":"11","author":"M Roschewski","year":"2014","unstructured":"Roschewski, M., Staudt, L. M., & Wilson, W. H. (2014). Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nature reviews. Clinical Oncology, 11(1), 12\u201323. doi: 10.1038\/nrclinonc.2013.197 .","journal-title":"Clinical Oncology"},{"key":"9581_CR23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","volume":"30","author":"AL Shaffer","year":"2012","unstructured":"Shaffer, A. L., Young, R. M., & Staudt, L. M. (2012). Pathogenesis of human B cell lymphomas. Annual Review of Immunology, 30, 565\u2013610. doi: 10.1146\/annurev-immunol-020711-075027 .","journal-title":"Annual Review of Immunology"},{"key":"9581_CR24","doi-asserted-by":"crossref","unstructured":"B\u00e9guelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K., Rosen, M., \u2026 Melnick, A. (2013). EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell, 23(5), 677\u2013692. doi: 10.1016\/j.ccr.2013.04.011 .","DOI":"10.1016\/j.ccr.2013.04.011"},{"key":"9581_CR25","doi-asserted-by":"crossref","unstructured":"Caganova, M., Carrisi, C., Varano, G., Mainoldi, F., Zanardi, F., Germain, P. L., \u2026 Casola, S. (2013). Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. Journal of Clinical Investigation, 123(12), 5009\u20135022. doi: 10.1172\/JCI70626 .","DOI":"10.1172\/JCI70626"},{"key":"9581_CR26","doi-asserted-by":"crossref","unstructured":"Morin, R.D., Johnson, N. a, Severson, T.M., Mungall, A.J., An, J., Goya, R., \u2026 Marra, M.A. (2010). Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics, 42(2), 181\u2013185. doi: 10.1038\/ng.518 .","DOI":"10.1038\/ng.518"},{"issue":"49","key":"9581_CR27","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","volume":"107","author":"CJ Sneeringer","year":"2010","unstructured":"Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010). Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 107(49), 20980\u201320985. doi: 10.1073\/pnas.1012525107 .","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9581_CR28","doi-asserted-by":"crossref","unstructured":"Cerchietti, L.C., Ghetu, A.F., Zhu, X., Da Silva, G.F., Zhong, S., Matthews, M., \u2026 Melnick, A. (2010). A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell, 17(4), 400\u2013411. doi: 10.1016\/j.ccr.2009.12.050 .","DOI":"10.1016\/j.ccr.2009.12.050"},{"key":"9581_CR29","doi-asserted-by":"crossref","unstructured":"McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G.S., \u2026 Creasy, C.L. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 492(7427), 108\u201312. doi: 10.1038\/nature11606 .","DOI":"10.1038\/nature11606"},{"key":"9581_CR30","doi-asserted-by":"crossref","unstructured":"Pfeifer, M., Grau, M., Lenze, D., Wenzel, S.S., Wolf, A., Wollert-Wulf, B., \u2026 Lenz, G. (2013). PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 110(30), 12420\u20135. doi: 10.1073\/pnas.1305656110 .","DOI":"10.1073\/pnas.1305656110"},{"key":"9581_CR31","doi-asserted-by":"crossref","unstructured":"Lenz, G., Wright, G.W., Emre, N.C.T., Kohlhammer, H., Dave, S.S., Davis, R.E., \u2026 Staudt, L.M. (2008). Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proceedings of the National Academy of Sciences of the United States of America, 105(36), 13520\u201313525. doi: 10.1073\/pnas.0804295105 .","DOI":"10.1073\/pnas.0804295105"},{"key":"9581_CR32","doi-asserted-by":"crossref","unstructured":"Iqbal, J., Meyer, P.N., Smith, L.M., Johnson, N.A., Vose, J.M., Greiner, T.C., \u2026 Chan, W.C. (2011). BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clinical Cancer Research, 17(24), 7785\u20137795. doi: 10.1158\/1078-0432.CCR-11-0267 .","DOI":"10.1158\/1078-0432.CCR-11-0267"},{"key":"9581_CR33","doi-asserted-by":"crossref","unstructured":"Souers, A.J., Leverson, J.D., Boghaert, E.R., Ackler, S.L., Catron, N.D., Chen, J., \u2026 Elmore, S.W. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 19(2), 202\u20138. doi: 10.1038\/nm.3048 .","DOI":"10.1038\/nm.3048"},{"key":"9581_CR34","doi-asserted-by":"crossref","unstructured":"Lenz, G., Davis, R.E., Ngo, V.N., Lam, L., George, T.C., Wright, G.W., \u2026 Staudt, L.M. (2008). Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (New York, N.Y.), 319(5870), 1676\u20131679. doi: 10.1126\/science.1153629 .","DOI":"10.1126\/science.1153629"},{"key":"9581_CR35","doi-asserted-by":"crossref","unstructured":"Compagno, M., Lim, W.K., Grunn, A., Nandula, S.V, Brahmachary, M., Shen, Q., \u2026 Pasqualucci, L. (2009). Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature, 459(7247), 717\u2013721. doi: 10.1038\/nature07968 .","DOI":"10.1038\/nature07968"},{"key":"9581_CR36","doi-asserted-by":"crossref","unstructured":"Kato, M., Sanada, M., Kato, I., Sato, Y., Takita, J., Takeuchi, K., \u2026 Ogawa, S. (2009). Frequent inactivation of A20 in B-cell lymphomas. Nature, 459(7247), 712\u2013716. doi: 10.1038\/nature07969 .","DOI":"10.1038\/nature07969"},{"key":"9581_CR37","doi-asserted-by":"crossref","unstructured":"Rimsza, L.M., LeBlanc, M.L., Unger, J.M., Miller, T.P., Grogan, T.M., Persky, D.O., \u2026 Gascoyne, R.D. (2008). Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood, 112(8), 3425\u20133433. doi: 10.1182\/blood-2008-02-137372 .","DOI":"10.1182\/blood-2008-02-137372"},{"key":"9581_CR38","doi-asserted-by":"crossref","unstructured":"Meyer, P.N., Fu, K., Greiner, T.C., Smith, L.M., Delabie, J., Gascoyne, R.D., \u2026 Weisenburger, D.D. (2011). Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. Journal of Clinical Oncology, 29(2), 200\u2013207. doi: 10.1200\/JCO.2010.30.0368 .","DOI":"10.1200\/JCO.2010.30.0368"},{"key":"9581_CR39","doi-asserted-by":"crossref","unstructured":"Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., \u2026 Chan, W.C. (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103(1), 275\u2013282. doi: 10.1182\/blood-2003-05-1545 .","DOI":"10.1182\/blood-2003-05-1545"},{"key":"9581_CR40","doi-asserted-by":"crossref","unstructured":"De Jong, D., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Lee, A., \u2026 Weller, E. (2007). Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications\u2014a study from the Lunenburg lymphoma biomarker consortium. Journal of Clinical Oncology, 25(7), 805\u2013812. doi: 10.1200\/JCO.2006.09.4490 .","DOI":"10.1200\/JCO.2006.09.4490"},{"issue":"4","key":"9581_CR41","first-page":"188","volume":"6","author":"G Held","year":"2009","unstructured":"Held, G., & Pfreundschuh, M. (2009). Hematology: germinal center or nongerminal center DLBCL? Nature reviews. Clinical Oncology, 6(4), 188\u2013190. doi: 10.1038\/nrclinonc.2009.22 .","journal-title":"Clinical Oncology"},{"key":"9581_CR42","doi-asserted-by":"crossref","unstructured":"Tilly, H., & Dreyling, M. (2010). Diffuse large B-cell non-Hodgkin\u2019s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: Official Journal of the European Society for Medical Oncology \/ ESMO, 21 Suppl 5(suppl_5), v172\u2013v174. doi: 10.1093\/annonc\/mdq203 .","DOI":"10.1093\/annonc\/mdq203"},{"issue":"1","key":"9581_CR43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3346\/jkms.2014.29.1.53","volume":"29","author":"HS Hwang","year":"2014","unstructured":"Hwang, H. S., Yoon, D. H., Suh, C., Park, C.-S., & Huh, J. (2014). Intestinal diffuse large B-cell lymphoma: an evaluation of different staging systems. Journal of Korean Medical Science, 29(1), 53\u201360. doi: 10.3346\/jkms.2014.29.1.53 .","journal-title":"Journal of Korean Medical Science"},{"issue":"27","key":"9581_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification. Journal of Clinical Oncology, 32(27), 1\u201310. doi: 10.1200\/JCO.2013.54.8800 .","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"9581_CR45","first-page":"368","volume":"55","author":"JO Armitage","year":"2005","unstructured":"Armitage, J. O. (2005). Staging non-Hodgkin lymphoma. CA: A Cancer Journal for Clinicians, 55(6), 368\u2013376. doi: 10.3322\/canjclin.55.6.368 .","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"9581_CR46","doi-asserted-by":"crossref","unstructured":"Shipp, M.A., Harrigton, D.P., Anderson, J.R., Bonadonna, G., Brittinger, G., Cabanillhas, F., & Canellhos, G.P. (1993). A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. The New England Journal of Medicine, 329. doi: 10.1056\/NEJM199309303291402 .","DOI":"10.1056\/NEJM199309303291402"},{"key":"9581_CR47","doi-asserted-by":"crossref","unstructured":"Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., \u2026 Connors, J.M. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109(5), 1857\u20131861. doi: 10.1182\/blood-2006-08-038257 .","DOI":"10.1182\/blood-2006-08-038257"},{"issue":"14","key":"9581_CR48","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M., & Loeffler, M. (2010). Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28(14), 2373\u20132380. doi: 10.1200\/JCO.2009.26.2493 .","journal-title":"Journal of Clinical Oncology"},{"key":"9581_CR49","doi-asserted-by":"crossref","unstructured":"Zhou, Z., Sehn, L.H., Rademaker, A.W., Gordon, L.I., LaCasce, A.S., Crosby-Thompson, A., \u2026 Winter, J.N. (2014). An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 123(6), 837\u2013842. doi: 10.1182\/blood-2013-09-524108 .","DOI":"10.1182\/blood-2013-09-524108"},{"key":"9581_CR50","doi-asserted-by":"crossref","unstructured":"M\u00fcller, C., Murawski, N., Wiesen, M. H. J., Held, G., Poeschel, V., Zeynalova, S., \u2026 Reiser, M. (2012). The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood, 119(14), 3276\u20133284. doi: 10.1182\/blood-2011-09-380949 .","DOI":"10.1182\/blood-2011-09-380949"},{"key":"9581_CR51","doi-asserted-by":"crossref","unstructured":"Maurer, M. J., Micallef, I. N. M., Cerhan, J. R., Katzmann, J. a., Link, B. K., Colgan, J. P., \u2026 Witzig, T. E. (2011). Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 29(12), 1620\u20131626. doi: 10.1200\/JCO.2010.29.4413 .","DOI":"10.1200\/JCO.2010.29.4413"},{"key":"9581_CR52","doi-asserted-by":"crossref","unstructured":"Sehn, L.H., Scott, D.W., Chhanabhai, M., Berry, B., Ruskova, A., Berkahn, L., \u2026 Gascoyne, R.D. (2011). Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. Journal of Clinical Oncology, 29(11), 1452\u20131457. doi: 10.1200\/JCO.2010.33.3419 .","DOI":"10.1200\/JCO.2010.33.3419"},{"key":"9581_CR53","doi-asserted-by":"crossref","unstructured":"Pfreundschuh, M., Ho, A.D., Cavallin-Stahl, E., Wolf, M., Pettengell, R., Vasova, I., \u2026 Kuhnt, E. (2008). Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group. The Lancet Oncology, 9(5), 435\u2013444. doi: 10.1016\/S1470-2045(08)70078-0 .","DOI":"10.1016\/S1470-2045(08)70078-0"},{"key":"9581_CR54","doi-asserted-by":"crossref","unstructured":"Carson, K.R., Bartlett, N.L., McDonald, J.R., Luo, S., Zeringue, A., Liu, J., \u2026 Colditz, G.A. (2012). Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 30(26), 3217\u20133222. doi: 10.1200\/JCO.2011.39.2100 .","DOI":"10.1200\/JCO.2011.39.2100"},{"key":"9581_CR55","doi-asserted-by":"crossref","unstructured":"Porrata, L.F., Ristow, K.M., Habermann, T.M., Witzig, T.E., Colgan, J.P., Inwards, D.J., \u2026 Markovic, S.N. (2014). Peripheral blood absolute lymphocyte\/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leukemia & Lymphoma, 55(12), 2728\u201338. doi: 10.3109\/10428194.2014.893313 .","DOI":"10.3109\/10428194.2014.893313"},{"key":"9581_CR56","doi-asserted-by":"crossref","unstructured":"Wilcox, R.A, Ristow, K., Habermann, T.M., Inwards, D.J., Micallef, I.N. M., Johnston, P.B., \u2026 Porrata, L. (2011). The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia\u202f: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 25(9), 1502\u20131509. doi: 10.1038\/leu.2011.112","DOI":"10.1038\/leu.2011.112"},{"key":"9581_CR57","doi-asserted-by":"crossref","unstructured":"Drake, M. T., Maurer, M.J., Link, B.K., Habermann, T.M., Ansell, S.M., Micallef, I.N., \u2026 Cerhan, J.R. (2010). Vitamin D insufficiency and prognosis in non-Hodgkin\u2019s lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(27), 4191\u20134198. doi: 10.1200\/JCO.2010.28.6674 .","DOI":"10.1200\/JCO.2010.28.6674"},{"key":"9581_CR58","doi-asserted-by":"crossref","unstructured":"Hong, F., Habermann, T.M., Gordon, L.I., Hochster, H., Gascoyne, R.D., Morrison, V.A., \u2026 Kahl, B.S. (2014). The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Annals of Oncology, 25(3), 669\u2013674. doi: 10.1093\/annonc\/mdt594 .","DOI":"10.1093\/annonc\/mdt594"},{"key":"9581_CR59","doi-asserted-by":"crossref","unstructured":"Persky, D.O., Unger, J.M., Spier, C.M., Stea, B., LeBlanc, M., McCarty, M.J., \u2026 Miller, T.P. (2008). Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. Journal of Clinical Oncology, 26(14), 2258\u20132263. doi: 10.1200\/JCO.2007.13.6929 .","DOI":"10.1200\/JCO.2007.13.6929"},{"key":"9581_CR60","doi-asserted-by":"crossref","unstructured":"Phan, J., Mazloom, A., Medeiros, L.J., Zreik, T.G., Wogan, C., Shihadeh, F., \u2026 Dabaja, B.S. (2010). Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. Journal of Clinical Oncology, 28(27), 4170\u20134176. doi: 10.1200\/JCO.2009.27.3441 .","DOI":"10.1200\/JCO.2009.27.3441"},{"issue":"15","key":"9581_CR61","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","volume":"22","author":"SJ Horning","year":"2004","unstructured":"Horning, S. J., Weller, E., Kim, K., Earle, J. D., O\u2019Connell, M. J., Habermann, T. M., & Glick, J. H. (2004). Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin\u2019s lymphoma: Eastern Cooperative Oncology Group Study 1484. Journal of Clinical Oncology, 22(15), 3032\u20133038. doi: 10.1200\/JCO.2004.06.088 .","journal-title":"Journal of Clinical Oncology"},{"key":"9581_CR62","unstructured":"Zelenetz, A.D., Wierda, W.G., Abramson, J.S., Advani, R.H., Andreadis, C.B., Bartlett, N., \u2026 Naganuma, M. (2013). Non-Hodgkin\u2019s lymphomas, version 1.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 11(3), 257\u201372; quiz 273. Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23486452 ."},{"key":"9581_CR63","doi-asserted-by":"crossref","unstructured":"Miller, T.P., Dahlberg, S., Cassady, J.R., Adelstein, D.J., Spier, C.M., Grogan, T.M., \u2026 Fisher, R.I. (1998). Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. The New England Journal of Medicine, 339(1), 21\u201326. doi: 10.1056\/NEJM199807023390104 .","DOI":"10.1056\/NEJM199807023390104"},{"issue":"5","key":"9581_CR64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PPO.0b013e31826c5907","volume":"18","author":"LH Sehn","year":"2012","unstructured":"Sehn, L. H. (2012). Chemotherapy alone for localized diffuse large B-cell lymphoma. The Cancer Journal, 18(5), 421\u2013426. doi: 10.1097\/PPO.0b013e31826c5907 .","journal-title":"The Cancer Journal"},{"issue":"4","key":"9581_CR65","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","volume":"85","author":"MV Maraldo","year":"2013","unstructured":"Maraldo, M. V., Aznar, M. C., Vogelius, I. R., Petersen, P. M., & Specht, L. (2013). Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma. International Journal of Radiation Oncology, Biology, Physics, 85(4), 1057\u20131065. doi: 10.1016\/j.ijrobp.2012.08.041 .","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"17","key":"9581_CR66","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.26687","volume":"118","author":"BA Campbell","year":"2012","unstructured":"Campbell, B. A., Connors, J. M., Gascoyne, R. D., Morris, W. J., Pickles, T., & Sehn, L. H. (2012). Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer, 118(17), 4156\u20134165. doi: 10.1002\/cncr.26687 .","journal-title":"Cancer"},{"key":"9581_CR67","doi-asserted-by":"crossref","unstructured":"Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., \u2026 Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346. doi: 10.1056\/NEJMoa011795 .","DOI":"10.1056\/NEJMoa011795"},{"key":"9581_CR68","doi-asserted-by":"crossref","unstructured":"Feugier, P., Van Hoof, A, Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferm\u00e9, C., \u2026 Coiffier, B. (2005). Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23(18), 4117\u20134126. doi: 10.1200\/JCO.2005.09.131 .","DOI":"10.1200\/JCO.2005.09.131"},{"key":"9581_CR69","doi-asserted-by":"crossref","unstructured":"Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., \u2026 Loeffler, M. (2008). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology, 9(2), 105\u2013116. doi: 10.1016\/S1470-2045(08)70002-0 .","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"9581_CR70","doi-asserted-by":"crossref","unstructured":"Maurer, M.J., Ghesqui\u00e8res, H., Jais, J.P., Witzig, T.E., Haioun, C., Thompson, C.A., \u2026 Cerhan, J.R. (2014). Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. Journal of Clinical Oncology, 32(10), 1066\u20131073. doi: 10.1200\/JCO.2013.51.5866 .","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"9581_CR71","doi-asserted-by":"crossref","unstructured":"R\u00e9cher, C., Coiffier, B., Haioun, C., Molina, T.J., Ferm\u00e9, C., Casasnovas, O., \u2026 Tilly, H. (2011). Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. The Lancet, 378(9806), 1858\u20131867. doi: 10.1016\/S0140-6736(11)61040-4 .","DOI":"10.1016\/S0140-6736(11)61040-4"},{"key":"9581_CR72","doi-asserted-by":"crossref","unstructured":"Andr\u00e9, M., Mounier, N., Leleu, X., Sonet, A., Brice, P., Henry-Amar, M., \u2026 Gisselbrecht, C. (2004). Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A GELA cohort study on 2837 patients. Blood, 103(4), 1222\u20131228. doi: 10.1182\/blood-2003-04-1124 .","DOI":"10.1182\/blood-2003-04-1124"},{"key":"9581_CR73","doi-asserted-by":"crossref","unstructured":"Cunningham, D., Hawkes, E.A., Jack, A., Qian, W., Smith, P., Mouncey, P., \u2026 Linch, D. (2013). Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. The Lancet, 381(9880), 1817\u20131826. doi: 10.1016\/S0140-6736(13)60313-X .","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"9581_CR74","doi-asserted-by":"crossref","unstructured":"Delarue, R., Tilly, H., Mounier, N., Petrella, T., Salles, G., Thieblemont, C., \u2026 Bosly, A. (2013). Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. The Lancet Oncology, 14(6), 525\u2013533. doi: 10.1016\/S1470-2045(13)70122-0","DOI":"10.1016\/S1470-2045(13)70122-0"},{"key":"9581_CR75","doi-asserted-by":"crossref","unstructured":"Gang, A.O., Str\u00f8m, C., Pedersen, M., d\u2019Amore, F., Pedersen, L.M., Bukh, A., \u2026 Nully Brown, P. (2012). R-choep-14 improves overall survival in young high-risk patients with diffuse large b-cell lymphoma compared with r-chop-14. A population-based investigation from the danish lymphoma group. Annals of Oncology, 23(1), 147\u2013153. doi: 10.1093\/annonc\/mdr058 .","DOI":"10.1093\/annonc\/mdr058"},{"key":"9581_CR76","doi-asserted-by":"crossref","unstructured":"Pfreundschuh, M., Kuhnt, E., Tr\u00fcmper, L., \u00d6sterborg, A., Trneny, M., Shepherd, L., \u2026 Murawski, N. (2011). CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology, 12(11), 1013\u20131022. doi: 10.1016\/S1470-2045(11)70235-2 .","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"9581_CR77","doi-asserted-by":"crossref","unstructured":"Wilson, W.H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S.M., \u2026 Janik, J.E. (2008). Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. Journal of Clinical Oncology, 26(16), 2717\u20132724. doi: 10.1200\/JCO.2007.13.1391 .","DOI":"10.1200\/JCO.2007.13.1391"},{"key":"9581_CR78","doi-asserted-by":"crossref","unstructured":"Wilson, W.H., Jung, S.H., Porcu, P., Hurd, D., Johnson, J., Eric Martin, S., \u2026 Hsi, E.D. (2012). A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica, 97(5), 758\u2013765. doi: 10.3324\/haematol.2011.056531 .","DOI":"10.3324\/haematol.2011.056531"},{"key":"9581_CR79","doi-asserted-by":"crossref","unstructured":"Martinelli, G., Gigli, F., Calabrese, L., Ferrucci, P. F., Zucca, E., Crosta, C., \u2026 Moreno Gomez, H. (2009). Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected]. Leukemia & Lymphoma, 50(6), 925\u2013931. doi: 10.1080\/10428190902912478 .","DOI":"10.1080\/10428190902912478"},{"key":"9581_CR80","doi-asserted-by":"crossref","unstructured":"Bonnet, C., Fillet, G., Mounier, N., Ganem, G., Molina, T.J., Thi\u00e9blemont, C., \u2026 Reyes, F. (2007). CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Journal of Clinical Oncology, 25(7), 787\u2013792. doi: 10.1200\/JCO.2006.07.0722 .","DOI":"10.1200\/JCO.2006.07.0722"},{"key":"9581_CR81","doi-asserted-by":"crossref","unstructured":"Ballonoff, A., Rusthoven, K.E., Schwer, A., McCammon, R., Kavanagh, B., Bassetti, M., \u2026 Rabinovitch, R. (2008). Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. International Journal of Radiation Oncology Biology Physics, 72(5), 1465\u20131471. doi: 10.1016\/j.ijrobp.2008.02.068 .","DOI":"10.1016\/j.ijrobp.2008.02.068"},{"key":"9581_CR82","doi-asserted-by":"crossref","unstructured":"Ferreri, A.J., Dell\u2019Oro, S., Reni, M., Ceresoli, G.L., Cozzarini, C., Ponzoni, M., & Villa, E. (2000). Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas. Oncology, 58(3), 219\u2013226.","DOI":"10.1159\/000012104"},{"issue":"4","key":"9581_CR83","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0360-3016(00)00760-4","volume":"48","author":"PJ Schlembach","year":"2000","unstructured":"Schlembach, P. J., Wilder, R. B., Tucker, S. L., Ha, C. S., Rodriguez, M. A., Hess, M. A., & Cox, J. D. (2000). Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. International Journal of Radiation Oncology Biology Physics, 48(4), 1107\u20131110. doi: 10.1016\/S0360-3016(00)00760-4 .","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"key":"9581_CR84","doi-asserted-by":"crossref","unstructured":"Horwitz, S.M., Negrin, R.S., Blume, K.G., Breslin, S., Stuart, M.J., Stockerl-Goldstein, K.E., \u2026 Horning, S.J. (2004). Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood, 103(3), 777\u2013783. doi: 10.1182\/blood-2003-04-1257 .","DOI":"10.1182\/blood-2003-04-1257"},{"key":"9581_CR85","doi-asserted-by":"crossref","unstructured":"Shi, Z., Das, S., Okwan-Duodu, D., Esiashvili, N., Flowers, C., Chen, Z., \u2026 Khan, M.K. (2013). Patterns of failure in advanced stage diffuse large b-cell lymphoma patients after complete response to r-chop immunochemotherapy and the emerging role of consolidative radiation therapy. International Journal of Radiation Oncology Biology Physics, 86(3), 569\u2013577. doi: 10.1016\/j.ijrobp.2013.02.007 .","DOI":"10.1016\/j.ijrobp.2013.02.007"},{"issue":"3","key":"9581_CR86","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijrobp.2011.12.067","volume":"84","author":"JA Dorth","year":"2012","unstructured":"Dorth, J. A., Prosnitz, L. R., Broadwater, G., Diehl, L. F., Beaven, A. W., Coleman, R. E., & Kelsey, C. R. (2012). Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. International Journal of Radiation Oncology Biology Physics, 84(3), 762\u2013767. doi: 10.1016\/j.ijrobp.2011.12.067 .","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"1","key":"9581_CR87","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1748-717X-7-100","volume":"7","author":"JA Dorth","year":"2012","unstructured":"Dorth, J. A., Prosnitz, L. R., Broadwater, G., Beaven, A. W., & Kelsey, C. R. (2012). Radiotherapy dose\u2013response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy. Radiation Oncology, 7(1), 100. doi: 10.1186\/1748-717X-7-100 .","journal-title":"Radiation Oncology"},{"key":"9581_CR88","doi-asserted-by":"crossref","unstructured":"Reyes, F., Lepage, E., Ganem, G., Molina, T.J., Brice, P., Coiffier, B., \u2026 Tilly, H. (2005). ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. The New England Journal of Medicine, 352(12), 1197\u20131205. doi: 10.1056\/NEJMoa042040 .","DOI":"10.1056\/NEJMoa042040"},{"key":"9581_CR89","doi-asserted-by":"crossref","unstructured":"Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., \u2026 Hoskin, P. (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiotherapy and Oncology, 100(1), 86\u201392. doi: 10.1016\/j.radonc.2011.05.013 .","DOI":"10.1016\/j.radonc.2011.05.013"},{"key":"9581_CR90","unstructured":"Boyle, J., Beaven, A.W., Diehl, L.F., Prosnitz, L.R., & Kelsey, C.R. (2014). Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy. Oncology (Williston Park, N.Y.), 28(12). Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25510806 ."},{"issue":"21","key":"9581_CR91","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1200\/JCO.2005.01.904","volume":"23","author":"ME Juweid","year":"2005","unstructured":"Juweid, M. E., & Cheson, B. D. (2005). Role of positron emission tomography in lymphoma. Journal of Clinical Oncology, 23(21), 4577\u20134580. doi: 10.1200\/JCO.2005.01.904 .","journal-title":"Journal of Clinical Oncology"},{"key":"9581_CR92","doi-asserted-by":"crossref","unstructured":"Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., \u2026 Cheson, B.D. (2007). Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. Journal of Clinical Oncology, 25(5), 571\u2013578. doi: 10.1200\/JCO.2006.08.2305 .","DOI":"10.1200\/JCO.2006.08.2305"},{"issue":"June","key":"9581_CR93","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/annonc\/mdi272","volume":"16","author":"NG Mikhaeel","year":"2005","unstructured":"Mikhaeel, N. G., Hutchings, M., Fields, P. A., O\u2019Doherty, M. J., & Timothy, A. R. (2005). FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Annals of Oncology, 16(June), 1514\u20131523. doi: 10.1093\/annonc\/mdi272 .","journal-title":"Annals of Oncology"},{"issue":"5-6","key":"9581_CR94","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/10428190009113384","volume":"39","author":"NG Mikhaeel","year":"2000","unstructured":"Mikhaeel, N. G., Timothy, A. R., O\u2019Doherty, M. J., Hain, S., & Maisey, M. N. (2000). 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin\u2019s lymphoma-comparison with CT. Leukemia & Lymphoma, 39(5-6), 543\u2013553. doi: 10.3109\/10428190009113384 .","journal-title":"Leukemia & Lymphoma"},{"key":"9581_CR95","doi-asserted-by":"crossref","unstructured":"Noordijk, E.M., Carde, P., Dupouy, N., Hagenbeek, A., Krol, A. D.G., Kluin-Nelemans, J.C., \u2026 Henry-Amar, M. (2006). Combined-modality therapy for clinical stage I or II Hodgkin\u2019s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24(19), 3128\u201335. doi: 10.1200\/JCO.2005.05.2746 .","DOI":"10.1200\/JCO.2005.05.2746"},{"issue":"14","key":"9581_CR96","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","volume":"22","author":"G Bonadonna","year":"2004","unstructured":"Bonadonna, G., Bonfante, V., Viviani, S., Di Russo, A., Villani, F., & Valagussa, P. (2004). ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 22(14), 2835\u20132841. doi: 10.1200\/JCO.2004.12.170 .","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"01","key":"9581_CR97","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4236\/jct.2013.41034","volume":"04","author":"HM Zwam","year":"2013","unstructured":"Zwam, H. M. (2013). Involved nodal radiotherapy vs. involved field radiotherapy after chemotherapy in the treatment of early stage Hodgkin\u2019s lymphoma. Journal of Cancer Therapy, 04(01), 271\u2013279. doi: 10.4236\/jct.2013.41034 .","journal-title":"Journal of Cancer Therapy"},{"issue":"4","key":"9581_CR98","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0360-3016(94)90352-2","volume":"30","author":"A Avil\u00e9s","year":"1994","unstructured":"Avil\u00e9s, A., Delgado, S., Nambo, M. J., Alatriste, S., & D\u00edaz-Maqueo, J. (1994). Adjuvant radiotherapy to sites of previous bulky disease in patients stage iv diffuse large cell lymphoma. International Journal of Radiation Oncology Biology Physics, 30(4), 799\u2013803. doi: 10.1016\/0360-3016(94)90352-2 .","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"key":"9581_CR99","doi-asserted-by":"crossref","unstructured":"Avil\u00e9s, A., Neri, N., Delgado, S., P\u00e9rez, F., Nambo, M.J., Cleto, S., \u2026 Huerta-Guzm\u00e1n, J. (2005). Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy. Medical oncology (Northwood, London, England), 22(4), 383\u2013387. doi: 10.1385\/MO:22:4:383 .","DOI":"10.1385\/MO:22:4:383"},{"key":"9581_CR100","doi-asserted-by":"crossref","unstructured":"Avil\u00e9s, A., Fern\u00e1ndez, R., P\u00e9rez, F., Nambo, M. J., Neri, N., Talavera, A., \u2026 Cleto, S. (2004). Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improve outcome. Leukemia & Lymphoma, 45(7), 1385\u20131389. doi: 10.1080\/10428190410001667712 .","DOI":"10.1080\/10428190410001667712"},{"key":"9581_CR101","doi-asserted-by":"crossref","unstructured":"Held, G., Murawski, N., Ziepert, M., Fleckenstein, J., Poschel, V., Zwick, C., \u2026 Pfreundschuh, M. (2014). Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. Journal of Clinical Oncology, 32(11), 1112\u20131118. doi: 10.1200\/JCO.2013.51.4505 .","DOI":"10.1200\/JCO.2013.51.4505"},{"key":"9581_CR102","unstructured":"Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999). Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 94(2), 429\u2013433. Retrieved from http:\/\/www.bloodjournal.org\/content\/94\/2\/429.abstract ."},{"key":"9581_CR103","unstructured":"Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., \u2026 Verhoef, G. (2001). Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin\u2019s lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? Journal of Clinical Oncology, 19(2), 414\u2013419. Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11208833 ."},{"key":"9581_CR104","doi-asserted-by":"crossref","unstructured":"Ramalingam, S.S., Kotsakis, A., Tarhini, A.A., Heron, D.E., Smith, R., Friedland, D., \u2026 Argiris, A. (2013). A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 81(3), 416\u2013421. doi: 10.1016\/j.lungcan.2013.06.002 .","DOI":"10.1016\/j.lungcan.2013.06.002"},{"key":"9581_CR105","doi-asserted-by":"crossref","unstructured":"Barrington, S.F., Mikhaeel, N.G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S.P., \u2026 Cheson, B.D. (2014). Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 32(27), 3048\u20133058. doi: 10.1200\/JCO.2013.53.5229 .","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"9581_CR106","doi-asserted-by":"crossref","unstructured":"Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., \u2026 Diehl, V. (2007). Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25(5), 579\u2013586. doi: 10.1200\/JCO.2006.09.2403 .","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"9581_CR107","doi-asserted-by":"crossref","unstructured":"Juweid, M.E., Wiseman, G.A., Vose, J.M., Ritchie, J.M., Menda, Y., Wooldridge, J.E., \u2026 Cheson, B.D. (2005). Response assessment of aggressive non-Hodgkin\u2019s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. Journal of Clinical Oncology, 23(21), 4652\u20134661. doi: 10.1200\/JCO.2005.01.891 .","DOI":"10.1200\/JCO.2005.01.891"},{"issue":"3","key":"9581_CR108","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0360-3016(99)00051-6","volume":"44","author":"SS Kamath","year":"1999","unstructured":"Kamath, S. S., Marcus, R. B., Lynch, J. W., & Mendenhall, N. P. (1999). The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin\u2019s lymphoma. International Journal of Radiation Oncology Biology Physics, 44(3), 563\u2013568. doi: 10.1016\/S0360-3016(99)00051-6 .","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"9","key":"9581_CR109","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1586\/era.11.88","volume":"11","author":"RS Bindra","year":"2011","unstructured":"Bindra, R. S., & Yahalom, J. (2011). The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again. Expert Review of Anticancer Therapy, 11(9), 1367\u20131378. doi: 10.1586\/era.11.88 .","journal-title":"Expert Review of Anticancer Therapy"},{"key":"9581_CR110","doi-asserted-by":"crossref","unstructured":"Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., \u2026 Horning, S.J. (2006). Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24(19), 3121\u20133127. doi: 10.1200\/JCO.2005.05.1003 .","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"9581_CR111","doi-asserted-by":"crossref","unstructured":"Shenkier, T.N., Voss, N., Fairey, R., Gascoyne, R.D., Hoskins, P., Klasa, R., \u2026 Connors, J.M. (2002). Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. Journal of Clinical Oncology, 20(1), 197\u2013204. doi: 10.1200\/JCO.20.1.197 .","DOI":"10.1200\/JCO.20.1.197"},{"key":"9581_CR112","doi-asserted-by":"crossref","unstructured":"Peyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J. F., Castaigne, S., \u2026 Tilly, H. (2011). Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet Oncology, 12(5), 460\u2013468. doi: 10.1016\/S1470-2045(11)70069-9 .","DOI":"10.1016\/S1470-2045(11)70069-9"},{"issue":"13","key":"9581_CR113","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S1470-2045(11)70140-1","volume":"12","author":"R Kridel","year":"2011","unstructured":"Kridel, R., & Dietrich, P. Y. (2011). Prevention of CNS relapse in diffuse large B-cell lymphoma. The Lancet Oncology, 12(13), 1258\u20131266. doi: 10.1016\/S1470-2045(11)70140-1 .","journal-title":"The Lancet Oncology"},{"key":"9581_CR114","doi-asserted-by":"crossref","unstructured":"Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R., Bosly, A., \u2026 Reyes, F. (2003). Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102(13), 4284\u20134289. doi: 10.1182\/blood-2003-02-0542 .","DOI":"10.1182\/blood-2003-02-0542"},{"key":"9581_CR115","doi-asserted-by":"crossref","unstructured":"Abramson, J.S., Hellmann, M., Barnes, J.A., Hammerman, P., Toomey, C., Takvorian, T., \u2026 Hochberg, E.P. (2010). Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer, 116(18), 4283\u20134290. doi: 10.1002\/cncr.25278 .","DOI":"10.1002\/cncr.25278"},{"key":"9581_CR116","doi-asserted-by":"crossref","unstructured":"Ferreri, A.J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G.A., Frezzato, M., \u2026 Cavalli, F. (2009). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. The Lancet, 374(9700), 1512\u20131520. doi: 10.1016\/S0140-6736(09)61416-1 .","DOI":"10.1016\/S0140-6736(09)61416-1"},{"key":"9581_CR117","unstructured":"Brugiatelli, M., Bandini, G., Barosi, G., Lauria, F., Liso, V., Marchetti, M., Tura, S.,\u2026 Tura, S. (2006). Management of chronic lymphocytic leukemia: Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 91(1), 1662\u20131673. Retrieved from http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&NEWS=N&AN=2007009472 ."},{"issue":"1","key":"9581_CR118","first-page":"397","volume":"2012","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz, C. H. (2012). Interim PET-CT in the management of diffuse large B-cell lymphoma. Hematology\/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2012(1), 397\u2013401. doi: 10.1182\/asheducation-2012.1.397 .","journal-title":"Education Program"},{"key":"9581_CR119","unstructured":"Awan, U., Siddiqui, N., SaadUllah, M., Bashir, H., Farooqui, Z. S., Muzaffar, N., & Mahmmood, M.T. (2013). FDG-PET scan in assessing lymphomas and the application of Deauville Criteria. JPMA. The Journal of the Pakistan Medical Association, 63(6), 725\u201330. Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23901673 ."},{"issue":"6","key":"9581_CR120","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/annonc\/mdl099","volume":"17","author":"JO Armitage","year":"2006","unstructured":"Armitage, J. O., & Loberiza, F. R. (2006). Is there a place for routine imaging for patients in complete remission from aggressive lymphoma? Annals of Oncology, 17(6), 883\u2013884. doi: 10.1093\/annonc\/mdl099 .","journal-title":"Annals of Oncology"},{"key":"9581_CR121","doi-asserted-by":"crossref","unstructured":"Kewalramani, T., Zelenetz, A.D., Nimer, S.D., Portlock, C., Straus, D., Noy, A., \u2026 Moskowitz, C.H. (2004). Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 103(10), 3684\u20133688. doi: 10.1182\/blood-2003-11-3911 .","DOI":"10.1182\/blood-2003-11-3911"},{"key":"9581_CR122","doi-asserted-by":"crossref","unstructured":"Gisselbrecht, C., Glass, B., Mounier, N., Gill, D.S., Linch, D.C., Trneny, M., \u2026 Schmitz, N. (2010). Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28(27), 4184\u20134190. doi: 10.1200\/JCO.2010.28.1618 .","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"9581_CR123","unstructured":"Glass, B., Hasenkamp, J., Wulf, G., Dreger, P., Pfreundschuh, M., Gramatzki, M., \u2026 Schmitz, N. (2012). Oral Abstract Session , Sat, 3\u202f: 00 PM-6\u202f: 00 PM High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma\u202f: results of a prospective study of the German high-grade non-H. Journal of Clinical Oncology, Retrieved from http:\/\/meetinglibrary.asco.org\/content\/99784-114 ."},{"key":"9581_CR124","doi-asserted-by":"crossref","unstructured":"El Gnaoui, T., Dupuis, J., Belhadj, K., Jais, J.P., Rahmouni, A., Copie-Bergman, C., \u2026 Haioun, C. (2007). Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Annals of Oncology, 18(8), 1363\u20131368. doi: 10.1093\/annonc\/mdm133 .","DOI":"10.1093\/annonc\/mdm133"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-015-9581-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10555-015-9581-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-015-9581-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:20:16Z","timestamp":1559236816000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10555-015-9581-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,13]]},"references-count":124,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["9581"],"URL":"https:\/\/doi.org\/10.1007\/s10555-015-9581-1","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,13]]}}}